Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.35 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.35 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.33 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.33 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | REN | P00797 | 1/20 | 0.33 |
| ▸ | ACE | P12821 | 1/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP3 | P08254 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12820309 | 0.84 | TSHR (0.42) | EGLN1TSHRTET2TGFBR1ALDH1A1 | |
| SCHEMBL17687578 | 0.82 | — | — | |
| SCHEMBL5067116 | 0.80 | SLC22A6 (0.33) | SLC22A6CACNA2D1CACNB3CACNA1CCYP1A2 | |
| SCHEMBL1301908 | 0.78 | EGLN1 (0.42) | EGLN1TSHRALDH1A1 | |
| SCHEMBL126426 | 0.77 | SMN1; SMN2 (0.48) | EGLN1TSHRTGFBR1SLC22A6TDP1 | |
| SCHEMBL457924 | 0.76 | ESRRB (0.44) | SLC22A6CACNA2D1CACNB3CACNA1CCYP1A2 | |
| SCHEMBL1087838 | 0.76 | HSD17B10 (0.38) | EGLN1TSHRTET2TGFBR1MMP1 | |
| SCHEMBL2577494 | 0.76 | ESRRB (0.44) | SLC22A6CACNA2D1CACNB3CACNA1CCYP1A2 | |
| SCHEMBL5019083 | 0.76 | ESRRB (0.44) | SLC22A6CACNA2D1CACNB3CACNA1CCYP1A2 | |
| SCHEMBL5391851 | 0.76 | HSD17B10 (0.38) | EGLN1TSHRTET2TGFBR1MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 231 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3796922-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A SELENO AMINO ACID COMPOUND FOR USE IN COMBINATION WITH ANOTHER AGENT FOR THE TREATMENT OF LIVER OR PANCREAS CANCER | SELEQ OY (FI) | 2026-03-18 | — | — | EP | claimed |
| US-12310936-B2 | Pharmaceutical compositions for the treatment of cancer | SELEQ OY (FI) | 2025-05-27 | — | — | US | claimed |
| US-20240033237-A1 | USE OF A-KETOGLUTARATE IN MANUFACTURE OF MEDICAMENT | TONGJI UNIVERSITY (CN) | 2024-02-01 | — | — | US | claimed |
| EP-3218010-B1 | POLYMER COMPOSED OF REPEAT UNITS HAVING A BIOLOGICALLY ACTIVE MOLECULE ATTACHED THERETO VIA A PH-SENSITIVE BOND | SPIREA LTD (GB) | 2022-10-26 | — | — | EP | claimed |
| CN-114981412-A | Metabolic guided permanent lineage specification during endothelial cell to hematopoietic cell transition | AMNIOTICS公司 | 2022-08-30 | — | — | CN | claimed |
| CN-114410573-A | Oocyte in-vitro maturation culture solution additive and application thereof | 内蒙古大学 | 2022-04-29 | — | — | CN | claimed |
| US-11203739-B2 | Modulating cell proliferation and pluripotency | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2021-12-21 | — | — | US | claimed |
| US-20210220310-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CANCER | SELEQ OY (FI) | 2021-07-22 | — | — | US | claimed |
| WO-2021129649-A1 | USE OF α-KETOGLUTARATE IN PREPARATION OF DRUG | 同济大学 | 2021-07-01 | — | — | WO | claimed |
| CN-113018288-A | Use of alpha-ketoglutaric acid in the manufacture of a medicament | 同济大学 | 2021-06-25 | — | — | CN | claimed |
| US-10709717-B2 | Polymer composed of repeat units having a biologically active molecule attached thereto via a pH-sensitive bond | SPIREA LIMITED (GB) | 2020-07-14 | — | — | US | claimed |
| US-20200188431-A1 | GLUTAMINE DEHYDROGENASE INHIBITORS FOR USE IN MUSCLE REGENERATION | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2020-06-18 | — | — | US | claimed |
| EP-3635115-A1 | GLUTAMINE DEHYDROGENASE INHIBITORS FOR USE IN MUSCLE REGENERATION | VIB VZW (BE) | 2020-04-15 | — | — | EP | claimed |
| WO-2018224636-A1 | GLUTAMINE DEHYDROGENASE INHIBITORS FOR USE IN MUSCLE REGENERATION | VIB VZW (BE) | 2018-12-13 | — | — | WO | claimed |
| EP-3218010-A1 | POLYMER COMPOSED OF REPEAT UNITS HAVING A BIOLOGICALLY ACTIVE MOLECULE ATTACHED THERETO VIA A PH-SENSITIVE BOND | Spirea Limited (GB) | 2017-09-20 | — | — | EP | claimed |
| US-20170224828-A1 | POLYMER COMPOSED OF REPEAT UNITS HAVING A BIOLOGICALLY ACTIVE MOLECULE ATTACHED THERETO VIA A PH-SENSITIVE BOND | SPIREA LIMITED (GB) | 2017-08-10 | — | — | US | claimed |
| US-20160250249-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR MODULATING AUTOPHAGY IN A SUBJECT IN NEED THEREOF | ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP) (FR) | 2016-09-01 | — | — | US | claimed |
| EP-3052133-A2 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR MODULATING AUTOPHAGY IN A SUBJECT IN NEED THEREOF | INSERM - Institut National de la Santé et de la Recherche Médicale (FR) | 2016-08-10 | — | — | EP | claimed |
| WO-2016059391-A1 | POLYMER COMPOSED OF REPEAT UNITS HAVING A BIOLOGICALLY ACTIVE MOLECULE ATTACHED THERETO VIA A PH-SENSITIVE BOND | OUBERAI MYRIAM MARIE (GB) | 2016-04-21 | — | — | WO | claimed |
| WO-2015049365-A2 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR MODULATING AUTOPHAGY IN A SUBJECT IN NEED THEREOF | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2015-04-09 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170224828-A1 | POLYMER COMPOSED OF REPEAT UNITS HAVING A BIOLOGICALLY ACTIVE MOLECULE ATTACHED THERETO VIA A PH-SENSITIVE BOND | IL1R1, SRRM2, H1-2 | EGLN1 1269/4885TSHR 372/4885TET2 1247/4885 |
| US-20210220310-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CANCER | RNASE1, SELENOI, GLS2 | EGLN1 2619/4885TSHR 2063/4885TET2 4351/4885 |
| US-20160250249-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR MODULATING AUTOPHAGY IN A SUBJECT IN NEED THEREOF | BECN1, ATG7, SQSTM1 | EGLN1 3024/4885TSHR 4684/4885TET2 4739/4885 |
| US-20200188431-A1 | GLUTAMINE DEHYDROGENASE INHIBITORS FOR USE IN MUSCLE REGENERATION | GLUL, GLS2, GLS | EGLN1 602/4885TSHR 3826/4885TET2 571/4885 |
| US-10709717-B2 | Polymer composed of repeat units having a biologically active molecule attached thereto via a pH-sensitive bond | IL1R1, SRRM2, H1-2 | EGLN1 1269/4885TSHR 372/4885TET2 1247/4885 |
| US-12310936-B2 | Pharmaceutical compositions for the treatment of cancer | RNASE1, SELENOI, GLS2 | EGLN1 2619/4885TSHR 2063/4885TET2 4351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.